Search results

911 results

Sorted by Relevance . Sort by Date

  1. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

     April 2020: This guidance has been withdrawn while the MHRA conducts an investigation into the MAGEC system. The MHRA issued a Medical Device Alert MDA/2020/011 for all MAGEC systems. This is in response to the manufacturer’s latest Field Safety Notice and previous field safety notices for problems that may require early removal of devices and lead to inadequate treatment. The MHRA is not recommending prophylactic removal of devices but the supply of all MAGEC systems is suspended in the UK while the MHRA investigation is ongoing. The MHRA has set out the following actions: Do not implant MAGEC rods in the UK until further notice. Identify all patients implanted with a MAGEC System and ensure systems are in place to follow up these patients.

  2. Four commonly used methods to increase physical activity (PH2)

    This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines:

  3. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (IPG177)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery

  4. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184)

    Evidence-based recommendations on high-intensity focused ultrasound for atrial fibrillation (AF) in association with other cardiac surgery

  5. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions)